



Department of Health Care Finance
825 North Capitol St. NE
Conference Room 4131
Washington DC, 20002



**PHARMACY & THERAPEUTICS
COMMITTEE MEETING**

March 4, 2010

Time: 2:30 pm – 5:30 pm

- | | |
|---|--|
| 1) Call to Order | Dr. Robert Vowels, MD |
| 2) Minutes of Previous Meeting | Charlene Fairfax, R.Ph. |
| 3) Comments from Interested Parties* | Charlene Fairfax, R.Ph. |
| 4) Clinical Drug Class Reviews | Kathy Novak, R.Ph. |
|
 | |
| Rapid-Acting Insulin | Hematopoietic Agents |
| Long Acting Insulin | Multiple Sclerosis Agents |
| Insulin Mix Products | Topical Retinoids |
| Insulin 70/30 | Cholinesterase Inhibitors (Alzheimer's Agents) |
| Insulin N | NMDA Receptor Antagonists (Namenda) |
| Insulin R | Non-Ergot Dopamine Receptor Antagonists |
| Carbamazepine Derivative Anticonvulsants | Histamine-2-Receptor Antagonists |
| First Generation Anticonvulsants | Benzoyl Peroxide/Clindamycin Products |
| Second Generation Anticonvulsants | Aczone |
| Progestins for Cachexia | Ulcerative Colitis Agents (Oral and Rectal) |
| Alpha Blockers for BPH | Proton Pump Inhibitors |
|
 | |
| 5) Executive Session (Committee Only) ** | Charlene Fairfax, R.Ph.
Sandy Kapur, Pharm.D. |
| 6) Final Recommendations of Preferred Drugs*** | Sandy Kapur, Pharm.D. |
| 7) Announcement of Next Scheduled P&T Committee Meeting | Dr. Robert Vowels |
| ▪ June 3, 2010 | |
| 8) Final Comments and Adjournment | Dr. Robert Vowels |

***Individuals wishing to make oral presentations to the Committee will be limited to three**

(3) minutes only

**** Closed Session**

*****Open Session**